Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.70
-$0.16-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.73% | 63.62% | |||
| Depreciation & Amortization | 1,275.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.19% | 73.92% | |||
| Operating Income | 8.19% | -73.92% | |||
| Income Before Tax | 8.17% | -73.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.17% | -73.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.17% | -73.91% | |||
| EBIT | 8.19% | -73.92% | |||
| EBITDA | 8.31% | -73.93% | |||
| EPS Basic | 18.34% | -17.08% | |||
| Normalized Basic EPS | 18.34% | -17.09% | |||
| EPS Diluted | 18.34% | -17.08% | |||
| Normalized Diluted EPS | 18.34% | -17.09% | |||
| Average Basic Shares Outstanding | 12.47% | 48.52% | |||
| Average Diluted Shares Outstanding | 12.47% | 48.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||